SCHEMBL16328070

SCHEMBL16328070

CCCOCCOCC(=O)N1CCc2c(nc(C)n(C(c3ccccc3)c3ccccc3)c2=O)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.38
▸ CYP3A4 P08684 2/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ USP2 O75604 1/20 0.34
▸ LDHA P00338 1/20 0.34
▸ CCR5 P51681 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ CREBBP Q92793 1/20 0.33
▸ PDE3B Q13370 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ NOTUM Q6P988 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ PLA2G4A P47712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249890 0.91 NPC1 (0.40) NPC1CYP3A4CYP2D6USP2LDHA
SCHEMBL13249901 0.88 NPC1 (0.40) NPC1CYP3A4CYP2D6USP2LDHA
SCHEMBL13249891 0.87 CYP3A4 (0.46) NPC1CYP3A4CYP2D6USP2LDHA
SCHEMBL13249873 0.85 MEN1 (0.45) USP2LDHAMEN1KMT2AMAPT
SCHEMBL13249798 0.85 PPARG (0.41) MEN1KMT2ALMNACNR2MAPT
SCHEMBL13249892 0.85 PTGDR2 (0.41) NPC1CCR5MEN1KMT2ARAB9A
SCHEMBL13249900 0.84 PTGDR2 (0.38) NPC1CYP3A4CYP2D6USP2LDHA
SCHEMBL13249894 0.84 PTGDR2 (0.44) MEN1KMT2ACNR1CNR2
SCHEMBL13249786 0.83 TSHR (0.45) MEN1KMT2ALMNAMAPTTP53
SCHEMBL13249799 0.83 TP53 (0.40) LMNAPLA2G4ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 NPC1 875/4885CYP3A4 2495/4885CYP2D6 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback